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Abstract
Background: In addition to endogenous opioids, a number of peptide sequences, derived from
endogenous (hemorphins, alphaS1-casomorphin), and exogenous proteins (casomorphins,
exorphins) have been reported, possessing opioid activity. In the present work, we report the
identification of a new peptide, receptorphin (Tyr-Ile-Phe-Asn-Leu), derived from the sequence of
the second transmembrane loop of the opioid receptor. This sequence is unique for the opioid
receptor, and conserved in all species and receptor-types.
Results and Discussion: Receptorphin competes for opioid binding, presenting a kappa-receptor
interaction, while it binds equally to delta- and mu- opioid and somatostatin-binding sites, and
inhibits the cell proliferation of a number of human cancer cell lines, in a dose-dependent and
reversible manner, at the picomolar or the nanomolar range. Receptorphin shows a preferential
action on prostate cancer cells.
Conclusion: Our work identifies, for the first time a peptide, in a receptor sequence, possessing
ligand-agonistic activities. A hypothesis, based on receptorphin liberation after cell death, is
presented, which could tentatively explain the time-lag observed during opioid antiproliferative
action.
Background
Endogenous opioids derive from three main precursor
proteins, namely proenkephalin A, proenkephalin B or
prodynorphin and proopiomelanocortin (POMC),
through alternative post-translational processing. These
three precursor proteins give rise to at least seven endog-
enous opioid peptides [1]. All these peptides usually have
a very brief half-life, with the exception of beta-endor-
phin, and therefore it is believed to act locally. Opioid
binding sites, characterized pharmacologically, belong to
three main categories, namely delta, mu and kappa. Dif-
ferent subtypes at each opioid site were equally reported
(δ 1, δ 2, µ1, µ2, κ 1, κ 2, κ 3). A differential distribution of
each opioid site was found in the central and the periph-
eral nervous system [2], while each endogenous opioid
ligand binds with a different selectivity to each site [3,4].
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The molecular characterization of opioid receptors was
obtained in the '90s. The cDNA and the aminoacid se-
quence of the three main opioid receptors was reported,
and found to follow the general scheme of the seven
loops membrane receptors [5]. The homology among the
reported opioid receptor sequences varies between 50
and 64%. It is interesting to note that transmembrane
and intracellular domains, presents a greater homology
(~69%) as compared to that of their extracellular part
[5–7].
Opioids interfere with a number of physiological actions
in the nervous system, including nociception, cognition,
and release of hormones or neurotransmitters. In addi-
tion, a specific modulatory action of opioids was report-
ed in the peripheral nervous system [8,9], and immune-
related cells [10–12]. The biological actions of opioids
necessitate the presence of opioid receptors, their ligand
and the ligand-specific degradation system in the prox-
imity of their site of action. This is true for the nervous
and the immune system, while the hypothalamic-pitui-
tary portal circulation provides opioids to the pituitary
gland [13]. In addition, opioids act in other tissues, and
recent reports indicate that these agents possess potent
antiproliferative actions in tumor cells [14–22], inducing
arrest of cell proliferation and apoptosis [23–25]. β -en-
dorphin, an opioid peptide produced mainly by the pitu-
itary and the immune system, with a sufficiently high
biological half-life, and/or locally produced opioids were
proposed as potential endogenous opioid mediators of
this antiproliferative effect [15,17]. In addition to the en-
dogenous classical opioid peptides, a number of other
opioid agonists has been reported, derived from food
(exorphins) [26,27], hemoglobin (hemorphins) [28–31]
or milk-caseins (casomorphins) [16,32–39]. These pep-
tides can also compete for opioid binding, and decrease
cell proliferation in different human and animal cell sys-
tems, and could be additional sources of locally-acting
opioids. Finally, a number of synthetic peptides, usually
produced through combinatorial search of peptide li-
braries [40,41] have shown an increased affinity for one
or multiple opioid binding sites.
In the present work, we report another peptide, derived
from the conserved second transmembrane segment of
the opioid receptor, with potent antiproliferative activi-
ty, in different human cancer cell lines. Its sequence is
Tyr-Ile-Phe-Asn-Leu. We named it receptorphin, and we
report that it further competes for opioid agonist bind-
ing.
Results
Opioid receptor binding selectivity of receptorphin
Figure 1 (upper panel) shows the competition of recep-
torphin for opioid ligand binding on different sites in the
rat brain. As shown, the peptide displaces radiolabelled
DPDPE and DAGO (selective ligands for the delta and
mu opioid binding site) in a dose-dependent manner,
with IC50s of 8.25 ×  10-8 and 1.81 ×  10-7 M respectively.
In addition, [3H]U69-593 was equally displaced by re-
ceptorphin from kappa1 opioid sites. This peptide com-
petes equally with kappa3 opioid sites, as
[3H]diprenorphine binding, in the presence of micromo-
lar concentrations of DADLE (which masks kappa2, delta
and mu sites, on which the radioligand could equally
bind [4]) does not modify the competition curves of re-
ceptorphin. The analysis of the binding curves is present-
ed in Table 1.
Previous results have shown that opioid binding sites
could also been identified in a number of breast [17,19]
and prostate cell lines [38]. Binding of opioid agonists on
these sites induces a decrease of cell proliferation. Figure
1 (lower panel) shows the competition of receptorphin
for opioid binding on T47D cells. The interaction of the
peptide with the different subtypes of the kappa opioid
site was obtained by the use of a combination of radiola-
belled ligands (ethylketocyclazocine and diprenorphine)
and effectors (DADLE), as described under Material and
Methods. Receptorphin competes for binding to kappa
opioid sites, with a very high affinity, presenting in this
cell line too a main interaction with kappa1 and kappa3
subtypes, as microsomal concentrations of DADLE do
not modify substantially opioid binding. The interaction
of receptorphin with delta and mu sites in T47D cells was
inexistant, due to the minimal number of these sites in
T47D cells. In contrast, receptorphin displaces [3H]DP-
Figure 1
Displacement of different opioid ligands by receptorphin, in
T47D cells and rat brain membranes. Upper panels: Rat brain
membranes. Lower panels: T47D cells See text for condi-
tions of binding. Mean ± SEM of three experiments in dupli-
cate.BMC Pharmacology 2001, 1:9 http://www.biomedcentral.com/1471-2210/1/9
DPE and [3H]DAGO, in MCF7 cells, bearing delta and
mu binding sites. A summary of the interaction of recep-
torphin with opioid sites in other cell lines is presented in
Table 1.
Cell proliferation
The above results indicate that receptorphin competes
for opioid binding on human breast and prostate cancer
cells, bearing opioid receptors. A main effect of opioid
ligands in these cancer cell lines is the decrease of cell
proliferation [16,17,19,38]. We have therefore examined
the antiproliferative action of receptorphin, in the same
cell lines. Figure 2 and Table 2 present the effect of recep-
torphin on the proliferation of breast (MCF7 and T47D)
and prostate cancer derived cell lines (PC3 and DU145).
As shown, this peptide, at concentrations ranging from
10-12 to 10-6 M inhibits cell proliferation of breast (MCF7
and T47D) and prostate (DU145, PC3) cell lines by 41, 49,
59 and 27% respectively. IC50 was 0.15, 0.07, 0.44 and
6.98 nM respectively. The general opioid antagonist di-
prenorphin (10-6 M) shifted the effect of receptorphin by
one log in breast cancer cell lines, while its action was
much more pronounced in DU145 and PC3 cancer cell
lines, indicating that opioid antagonists reverse, at least
partially the antiproliferative effect of the peptide. In
contrast, the selective kappa1 antagonist Nor-Binaltor-
phine (NorBNI) (10-6 M) produced only a partial inhibi-
tion of receptorphin binding. This result indicates that
receptorphin might interact equally with other sites, dif-
ferent from classical opioid receptors.
Interaction of receptorphin with other membrane receptor 
systems
As presented in Figure 2, the addition of the general opi-
oid antagonist diprenorphine in the culture medium de-
creases, but does not abolish the antiproliferative effect
of receptorphin. This result could suggest a possible in-
teraction of the peptide with other membrane sites, dif-
ferent from opioid binding sites. A similar result was
equally onserved with a number of casomorphins, in the
same cell lines [16,38]. Further analysis has revealed an
interaction of casomorphins with somatostatin binding
sites [16,38,42]. In order to identify a possible interac-
tion of receptorphin with somatostatin sites, we have
used the LNCaP prostate cancer cell line, which, accord-
ing to our previous results does not express opioid bind-
ing sites [38]. Our results are shown in Figure 3.
Receptorphin inhibited cell growth by 60%, with an IC50
of 87 nM, significantly higher than that observed for oth-
er cell lines. In this particular case, diprenorphine (10-6
M) enhanced rather than inhibited the antiproliferative
effect by a factor of 30 (IC50 2.8 nM), indicating that oth-
er membrane receptor systems might be also implicated
in the action of the peptide. Competition of receptorphin
for [125I]Tyr11-somatostatin14 binding revealed that the
peptide could decrease somatostatin binding with an
IC50 of 18.9 ± 1.02 ×  10-9 M, comparable with the anti-
proliferative effect of the peptide on LNCaP cells, indi-
cating a significant interaction of receptorphin with
somatostatin receptors.
Discussion
In recent years, a number of endogenous and food-de-
rived proteins have been identified as potential sources
of opioid or opiomimetic peptides. They include gluten,
hemoglobin and caseins [26,27,32–37,39]. By limited
proteolysis of such proteins, a number of peptides have
been identified, which presents features of opiomimetic
action: binding to opioid receptors, competition for opi-
oid ligands, opiomimetic effects, and reversion of their
action by the addition of opioid antagonists. These opio-
id peptide sources could resolve the problem of opioid
availability in organs, in which classical opioid precursor
were not identified. Indeed, the blood flow disposition of
Table 1: Inhibitory concentrations 50% (IC50) ± SE of receptorphin competition on different opioid sites, assayed by displacement bind-
ing of a variety of opioid ligands.
Opioid 
Source
DPDPE or 
DSLET
DAGO EKC Diprenorphin EKC +DADLE Diprenorphin 
+DADLE
MCF7 3.25 ± 0.42 ×  10-9 1.43 ± 0.20 ×  10-10 6.65 ± 1.01 ×  10-11 5.78 ± 0.64 ×  10-13 1.59 ± 0.14 ×  10-10 >10-12
T47D ND ND 5.14 ± 0.74 ×  10-10 >10-12 5.41 ± 0.57 ×  10-11 >10-12
DU145 ND 6.52 ± 0.58 ×  10-11 2.34 ± 0.55 ×  10-11 ND 2.87 ± 0.22 ×  10-11 ND
PC3 ND 4.30 ± 0.97 ×  10-11 >10-6 ND >10-6 ND
Rat 8.25 ± 0.81 ×  10-8 1.81 ± 0.23 ×  10-7 *1.85 ± 0.11 ×  10-10 **5.77 ± 0.87 ×  10-10 -1 . 8 5   ± 0.43 ×  10-10
Brain 2.65 ± 0.13 ×  10-9
*[3H]U60-593 was used as a selective kappa1 opioid ligand **Displacement curves were best fitted with a two-site model. See text for details. IC50s 
(in Moles/L) were calculated by sigmoidal fitting of displacement experiments. ND = not detected. Mean ± SE of three different experiments per-
formed in duplicate.BMC Pharmacology 2001, 1:9 http://www.biomedcentral.com/1471-2210/1/9
endogenous opioid peptides is limited, due to the very
short half-life of these peptides, with the exception of
beta-endorphin.
The results of the present investigation identify another
peptide, receptorphin, derived from the opioid receptor
itself. Receptorphin sequence is comprised to the con-
served structure of the second transmembrane segment
of the opioid receptor (see Table 3 and Figure 5). Recep-
torphin exhibits some characteristics of an opioid ligand:
1. It competes for opioid ligand binding on opioid sites,
exhibiting principally selectivity for kappa opioid recep-
tors (especially kappa1 and kappa3). Its affinity, in hu-
man breast and prostate cancer cell lines, is higher than
that of the prototype ligands [14,17,19]. In contrast, in rat
brain membranes, the affinity of receptorphin is lower
than that of DAGO or DPDPE. It is not actually known
whether this discrepancy is due to the difference of nor-
mal and neoplastic tissue, in which a possible alternative
splicing of the opioid receptor could occur, to the condi-
tions of binding (hypotonic medium in rat brain as com-
pared to isotonic medium in whole cell binding) or to
species differences. A similar discrepancy was also ob-
served in the case of α S1-casomorphin and other caso-
morphin peptides [16,37,38]. In addition, receptorphin
interacts with somatostatin binding, a result explaining
the non-complete reversion of its effect by opioid antag-
onists. A similar interaction was equally observed with a
number of other food-derived peptides, in the same sys-
tem [16,38].
2. Receptorphin decreases cell proliferation in different
breast and prostate cell lines, in a dose-dependent and
reversible manner, as reported for other opioid alkaloids
and casomorphin ligands [16,17,38]. Comparing the IC50
of receptorphin with that obtained in the same cell lines
by a number of other opioid peptides [16,37,38] it is de-
rived that this new opioid agonist is almost as potent as
alphaS1-casomorphin in the prostate, while it is much
less potent (at least by a factor of 20) in the breast. Com-
parable maximal inhibition of growth was obtained by
receptorphin and other casomorphin peptides, both in
the breast and the prostate [16,38], representing possi-
bly, the maximum opioid-related effect on these cell
lines. The physiological relevance of this prostate selec-
tivity of receptorphin is not known.
The above results are, of course, not enough to character-
ize fully a possible new opioid peptide. Further work, im-
plying more classical opioid effects in cells (GTP binding,
cAMP inhibition) and organs or animals might be neces-
sary for the complete identification of receptorphin as an
opioid agonist. Nevertheless, the fact that receptorphin
binds with a high affinity to opioid sites in different or-
gans (brain and cancer cell lines) in which opioid recep-
tors were identified, and its antiproliferative action in
different cancer cell lines is inhibited by the general opi-
oid antagonist diprenorphine apply for an opioid activity
of this peptide.
The sequence of receptorphin (Tyr-Ile-Phe-Asn-Leu) is
conserved in all reported opioid receptors, from a variety
of species (Table 3). In contrast, this sequence is restrict-
ed to the opioid receptor, and is not detected in other
seven-loop membrane receptors [43]. It is interesting
that, at the same position (second transmembrane seg-
ment) of the different types of the somatostatin receptor
(SSTR-1 to 5) which present the greater homology with
opioid receptors [5], in different species, a peptide with
the sequence Tyr-Ile(or-Leu)-Leu-Asn-Leu exists, pre-
senting an homology in structure with receptorphin [44–
48]. Furthermore, two or three amino acids of receptor-
phin (Phe-Asn-Leu) interfere with the agonist or antago-
nist binding, at least indirectly, participating in the
formation of the ligand envelope [43]. This might be the
reason of the conservation of the receptorphin sequence
in all opioid receptor sequences (Table 3). Comparing re-
ceptorphin (Tyr-Ile-Phe-Asn-Leu) with other opioid
peptides, it is observed that it shares Tyr at position 1 and
Leu in position 5. In contrast, the presence of Ile and Asn
at positions 2 and 4 and the non-classical Phe at position
Figure 2
Effect of receptorphin on the proliferation of breast (MCF7,
T47D) and prostate (DU145, PC3) human cancer cell lines.
Cells were plated at an initial density of 20000 cells/well, and
the effect of the peptide (changed every day) was assayed
after two cell cycles (4th day). The number of cells therefore,
in control conditions (in the absence of the peptide) was
80000/well. Cell viability was in all cases >95%. Diprenorphin
was added simultaneously with receptorphin, at a concentra-
tion of 10-6 M. Mean ± SEM of three different experiments
performed in triplicate.BMC Pharmacology 2001, 1:9 http://www.biomedcentral.com/1471-2210/1/9
3 are unique in receptorphin. This non-classical amino-
acid composition may confer the described binding char-
acteristics to this new peptide (Table 1), which bears the
classical pharmacophoric groups of classical opioid ago-
nists (Tyr, Phe, Leu).
Conclusions
In the present paper, we report the identification of a lig-
and-specific peptide, in the sequence of its cognitive re-
ceptor structure. Receptorphin (Tyr-Ile-Phe-Asn-Leu)
has a unique sequence, conserved in all opioid receptor
types and species. The peptide competes with a high af-
finity for opioid binding, showing a preferential interac-
tion with kappa (κ 1 and κ 3), while it competes with delta,
mu, and somatostatin sites with a lower affinity. It can
therefore be considered as a non-selective opioid ligand.
Although this finding is interesting per se, the current
knowledge permits only speculations about a possible bi-
ological role of the peptide, if any. Receptorphin is
flagged by Ile at position -1 and always by Ala at position
6 (see Figure 5), making it a putative target of peptidases,
while its location, in the hydrophobic membrane envi-
ronment, protects it from a possible hydrolytic-enzyme
action. A possible hypothesis could be that receptorphin
might act as an opioid peptide after cell death. In this
case, after intra- and extracellular domains of opioid re-
ceptor destruction by different liberated proteolytic en-
zymes, and rupture of the membrane structure, the
leading Ile-1 of receptorphin could be cleaved by ex-
opeptidases, while the following Ala6 might be removed
by basic endopeptidases, leading to the liberation of the
active peptide. If such a mechanism occurs, opioid action
could be potentiated after an opioid- and/or other induc-
ers-related cell death. Indeed, it is tentative to assume
that after an opioid mediated cellular death [23–25], re-
ceptorphin liberation might trigger a positive feedback
Table 2: Inhibitory concentrations 50% (IC50) and maximal inhibition of cell growth of different breast and prostate cancer cell lines by 
receptorphin.
Receptorphin Maximum Inhibition Receptorphin+ Diprenorphin Maximum Inhibition
MCF7 1.51 ± 0.18 ×  10-10 0.41 1.69 ± 0.10 ×  10-9 0.49
T47D 7.01 ± 0.36 ×  10-11 0.44 3.61 ± 0.13 ×  10-9 0.48
LNCaP 8.70 ± 0.87 ×  10-8 0.58 2.88 ± 0.15 ×  10-9 0.61
DU145 4.36 ± 0.19 ×  10-10 0.59 3.44 ± 2.32 ×  10-7 0.53
PC3 6.98 ± 0.11 ×  10-9 0.27 7.00 ± 0.14 ×  10-7 0.31
Curves were obtained by sigmoidal fitting of data presented in Figure 2. Concentrations are expressed in Moles/L. Mean ± SE of three different 
experiments performed in triplicate.
Table 3: Position of receptorphin in different reported opioid receptor sequences.
Receptor Source Length (a.a.) Receptorphin position Reference
Delta Zebrafish 373 90–94 [51]
Delta Human 372 87–91 [52]
Mu Human 400 98–102 [53][54][55]
Mu variant Human 392 107–112 [55]
Mu Mouse 367 86–90 [56]
Mu Rat 398 69–100 [57][58][59][60][61][62][63][64]
Mu Bovine 401 109–113 [65]
Kappa Rat 380 97–101 [66]
Kappa Guinea Pig 380 97–101 [67]
Kappa Mouse 380 97–101 [56]
Kappa Human 380 97–101 [68][69]
Orphan Human 370 89–93 [70][71]
Orphan Rat 357 86–90 [72]
Orphan Mouse 367 87–92 [56][73][74][75]
Orphan Rat 367 86–90 [76][77][78][79][80][81]BMC Pharmacology 2001, 1:9 http://www.biomedcentral.com/1471-2210/1/9
loop, propagating the opioid effects to a number of adja-
cent opioid receptor-positive cells. This mechanism
could possibly explain the time-lag found in opioid-relat-
ed cell proliferation and apoptosis, reported in a number
of malignant cell  lines [15–17,37,38]. Nevertheless, this
putative receptorphin implication in cell proliferation re-
mains highly speculative, until its presence could be de-
tected in cell cultures. In addition, it might be of interest
to detect similar structures in the sequence of other
members of the seven-loop superfamily, in order to in-
vestigate whether this finding is unique to the opioid re-
ceptor itself, or could be extended to its other members.
Methods
Peptide synthesis
Receptorphin (Tyr-Ile-Phe-Asn-Leu) was synthesized by
conventional peptide chemistry methods. t-butoxycar-
boxyl (Boc) groups were used for protection of the a-ami-
no-groups, while a t-butyl group was used for the
protection of the phenolic hydroxy-group. The dichloro-
carbodi-imiole/1-hydroxybenzo-triazo method was used
for the coupling of the protected amino acids. Removal of
the t-butyl and Boc groups was achieved by trifluoroace-
tic acid. Peptide purification was made by semiprepara-
tive HPLC on a reverse phase C-18 Nucleosil column, on
a 30 min linear gradient of 15–85% methanol in 0.1%
aqueous trifluoroacetic acid.
Cell lines and culture conditions
Two breast cancer (MCF7 and T47D), and tho prostate
cell lines (PC3 and DU145), bearing opioid binding sites
[16,17,19,38], were used, in order to assay the opioid ac-
tivity of receptorphin. DU145 and MCF7 cell lines were
purchased from DSMZ (Braunschweig, Germany), while
T47D, and PC3 cells were from the European Collection
of Cell Cultures (Salisbury, UK). T47D and DU145 cells
were cultured in RPMI-1640 medium supplemented
with 10% fetal bovine serum (FBS). PC3 cells were cul-
tured in DMEM medium with 10% FBS, while, for MCF7
cell culture, DMEM/F12 medium was used, supplement-
ed with 5 µg/ml insulin (Sigma, St Louis, MI) and 10%
FBS. All cell lines were maintained in a humidified at-
mosphere of 5% CO2 in air. All culture media were from
Gibco BRL (Life Technologies, Paisley, UK). Medium,
supplemented or not with receptorphin, was changed
every day. Without addition of any drug, the prolifera-
tion time of all cell lines was two days. Receptorphin was
dissolved in phosphate buffered saline shortly before
use.
Cell proliferation
Cells were plated in 24-well plates, at an initial density of
2 ×  104 cells, with 1.0 ml medium per well. All drugs were
added to cultures one day after seeding (designated as
day 0), in order to ensure uniform attachment of cells at
the onset of the experiments. Cell growth was measured
by the tetrazolium salt assay [49]. Cells were incubated
for 4 h at 37°C with the tetrazolium salt (3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyl  tetrazolium bromide), and
metabolically active cells reduced the dye to purple for-
mazan. Dark blue crystals were dissolved with propanol,
and the absorbance was measured at 570 nm and com-
pared against a standard curve of known numbers of
cells. All experiments were performed, at minimum,
three times in triplicate.
Binding conditions
Cancer cell lines
Ligand binding assays on whole cells (106 cells/well)
were performed as described in Hatzoglou et al
[14,16,17], in a total volume of 0.5 ml phosphate buffered
saline (10 mM phosphate, 150 mM NaCl, pH 7.4), con-
taining radioactive opioids or somatostatin, without (to-
tal binding), with 10-5 M of the same unlabelled agent
(non specific binding), or with varying concentrations of
receptorphin, ranging from 10-12 to 10-6 M. Cells were in-
cubated for 2 h at room temperature (18–22°C). At the
end of the incubation period, cells were washed twice
with cold buffer, in order to eliminate the unbound radi-
oactivity. Cells were removed from plates with 0.4 ml 2N
NaOH, mixed with 4 ml scintillation cocktail (SigmaFlu-
or, Sigma, St Louis, MI) and counted in a scintillation
counter (Tricarb, Series 4000, Packard), with a 60% effi-
Figure 3
Competition of receptorphin action by general and selective
opioid antagonists in T47D cells. T47D cells were plated at
an initial density of 20000 cells/well, and the effect of the
peptide (changed every day) was assayed after two cell cycles
(4th day). The number of cells therefore, in control condi-
tions (in the absence of the peptide) was 80000/well. Cell via-
bility was in all cases >95%. Diprenorphin (A) or NorBNI (B)
were added simultaneously with receptorphin, at a concen-
tration of 10-6 M. Mean ± SEM of three different experiments
performed in triplicate.BMC Pharmacology 2001, 1:9 http://www.biomedcentral.com/1471-2210/1/9
ciency for Tritium, for opioids and in a Tricarb (Packard)
gamma counter with a 95% efficiency for [125I] (somato-
statin binding). Binding was repeated three times (in du-
plicate).
A number of different opioid ligands were used in order
to identify specific opioid binding sites. [3H] [D-Pen2, D-
Pen5]enkephalin (DPDPE) was used as a selective delta
ligand, and [3H] [N-me-Phe4, Gly5-ol]enkephalin (DA-
GO) as a selective mu ligand. [3H]ethylketocyclazocine
(EKC) and [3H]diprenorphine were used as general opi-
oid ligands, sharing nevertheless, at nanomolar concen-
trations, a different receptor recognition spectrum:
ethylketocyclazocine recognizes delta, mu, and the
kappa1 and kappa2 (or epsilon) subtypes of the kappa
binding site, while diprenorphine recognizes delta, mu,
kappa2 and kappa3 sites [3,4]. The addition of micromo-
lar concentrations of DADLE masks the ligand interac-
tion with delta, mu, and kappa2 opioid sites, permitting
the differentiation of the effect of the tracer with the
kappa1 and the kappa3 opiod site respectively [3,4]. Con-
trol experiments, in our laboratory have proven that by
the use of these combinations we obtain similar results
for the detection of kappa1 and kappa3 opioid sites, as
with the use of the selective ligands U50488 and Met5-
enkephalin-Arg6-Phe7.
Rat brain membranes
Rat brain membrane preparation and opioid binding
was performed as described previously by Loukas et al.
[39]. Briefly, binding was performed in Tris-HCl buffer
(10 mM, pH 7.4), in a final volume of 1.0 ml. The protein
concentration was 300 µg/assay. Binding was initiated
by the addition of 2 nM of the selective ligand ([3H]DP-
DPE for δ  or [3H]DAGO for µ sites, [3H]U69-593 for
kappa1 site and [3H]diprenorphine as a general opioid
ligand, as discussed above). Non specific binding was es-
timated in the presence of 10-5 M naloxone or diprenor-
phin. Peptide concentrations varied from 10-12 to 10-6 M.
After the incubation, bound radioactivity was separated
by filtration, under reduced pressure, through GF/D fil-
ters, previously soaked in Tris-HCl buffer, and rinsed
twice with ice-cold buffer.
The results of binding assays were analyzed by the Origin
(MicroCal, Northampton, MA.) V 5 package, using equa-
tions described by Munson and Rodbard [50].
Radiochemicals and chemicals
[3H]ethylketocyclazocine (S.A. 18 Ci/mmol), [3H] [D-
Pen2, D-Pen5]enkephalin (DPDPE) (S.A. 37 Ci/mmol)
and [3H]U69-593 (S.A. 39.7 Ci/mmol) were bought from
New England Nuclear Co (Zaventum, Belgium). [3H]di-
prenorphine (S.A. 29 Ci/mmol), [3H] [N-me-Phe4, Gly5-
ol]enkephalin (DAGO, S.A. 47.7 Ci/mmol) and
[125I]Tyr11-somatostatin14 (S.A. 2000 Ci/mmol) were
from Amersham (Buckinghabshire, UK). Ethylketocycla-
zocine was a gift from Sterling-Winthrop. Diprenorphine
was from Reckit and Coleman Co. All other chemicals
Figure 4
Interaction of receptorphin with somatostatin binding sites.
A: Effect of receptorphin on the proliferation of LNCaP cells,
not-presenting opioid binding sites [38]. Conditions of cell
growth were similar with those presented in the legend of
Figure 2, with the exception that cells were assayed at day 6,
as the doubling time of LNCaP cells is longer (3.02d). Mean ±
SEM of three experiments in triplicate. B. Competition of
receptorphin for somatostatin binding. Displacement of radi-
olabelled [125I]Tyr11Somatostatin14 by varying concentra-
tions of receptorphin. See text for details of binding.
Figure 5
Alignment of the sequences of the second transmembrane
loop of different opioid receptors. Sequences are derived
from references in Table 3. The sequence of receptorphin is
indicated in bold letters.BMC Pharmacology 2001, 1:9 http://www.biomedcentral.com/1471-2210/1/9
were either from Merck (Darmstad, Germany) or from
Sigma (St Louis MO).
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